Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

JNJ

Johnson & Johnson

Mar 25 • 04:00PM ET

161.02

Dollar change -2.27
Percentage change -1.39	%

Healthcare • Drug Manufacturers - General • USA • NYSE

Peers: LLY PFE MRK AMGN BMY NVS ABBV GSK AZN MDT

| Held by: VTI VOO SPY IVV VTV XLV VIG VYM IWD VHT

Scroll to Statements

Index	DJIA, S&P 500	P/E	27.77	EPS (ttm)	5.80	Insider Own	0.13%	Shs Outstand	2.41B	Perf Week	-1.97%
Market Cap	388.03B	Forward P/E	14.58	EPS next Y	11.04	Insider Trans	-0.62%	Shs Float	2.41B	Perf Month	-1.66%
Income	14.07B	PEG	5.49	EPS next Q	2.65	Inst Own	72.99%	Short Float	0.96%	Perf Quarter	12.15%
Sales	88.82B	P/S	4.37	EPS this Y	5.73%	Inst Trans	0.72%	Short Ratio	2.57	Perf Half Y	-1.91%
Book/sh	29.70	P/B	5.42	EPS next Y	4.65%	ROA	8.09%	Short Interest	23.10M	Perf Year	3.38%
Cash/sh	10.18	P/C	15.82	EPS next 5Y	5.06%	ROE	20.06%	52W Range	140.68 - 169.99	Perf YTD	11.34%
Dividend Est.	5.02 (3.12%)	P/FCF	19.56	EPS past 5Y	0.55%	ROI	13.61%	52W High	-5.28%	Beta	0.50
Dividend TTM	4.96 (3.08%)	Quick Ratio	0.86	Sales past 5Y	2.03%	Gross Margin	68.71%	52W Low	14.46%	ATR (14)	2.53
Dividend Ex-Date	Feb 18, 2025	Current Ratio	1.11	EPS Y/Y TTM	3.69%	Oper. Margin	23.52%	RSI (14)	47.29	Volatility	1.31% 1.52%
Employees	138100	Debt/Eq	0.53	Sales Y/Y TTM	-4.51%	Profit Margin	15.84%	Recom	2.21	Target Price	169.61
Option/Short	Yes / Yes	LT Debt/Eq	0.45	EPS Q/Q	-15.14%	Payout	84.80%	Rel Volume	0.83	Prev Close	163.29
Sales Surprise	0.40%	EPS Surprise	2.43%	Sales Q/Q	5.27%	Earnings	Apr 15 BMO	Avg Volume	9.00M	Price	161.02
SMA20	-1.98%	SMA50	2.29%	SMA200	3.23%	Trades		Volume	7,456,197	Change	-1.39%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-10-24	Resumed	BofA Securities	Neutral	$166
Nov-15-24	Initiated	Wolfe Research	Outperform	$190
Jul-23-24	Downgrade	Daiwa Securities	Outperform → Neutral	$160 → $150
May-30-24	Resumed	Goldman	Neutral	$160
Apr-18-24	Upgrade	HSBC Securities	Hold → Buy	$170
Dec-13-23	Downgrade	Wells Fargo	Overweight → Equal Weight	$170 → $163
Dec-01-23	Upgrade	UBS	Neutral → Buy	$167 → $180
Oct-05-23	Initiated	RBC Capital Mkts	Outperform	$178
Sep-06-23	Initiated	HSBC Securities	Hold	$175
May-30-23	Resumed	Citigroup	Buy	$185
Mar-29-23	Initiated	UBS	Neutral	$164
Mar-01-23	Initiated	Guggenheim	Neutral	$161
Nov-18-22	Initiated	Credit Suisse	Neutral	$170
Oct-18-22	Initiated	Barclays	Equal Weight	$175
Oct-14-22	Reiterated	BofA Securities	Neutral	$185 → $178
Jun-22-22	Initiated	Daiwa Securities	Outperform
May-23-22	Resumed	SVB Leerink	Outperform	$200
Apr-06-22	Resumed	Morgan Stanley	Equal-Weight	$173
Mar-16-22	Downgrade	Bernstein	Outperform → Mkt Perform	$180 → $183
Mar-02-22	Resumed	BofA Securities	Neutral	$185

Show Previous Ratings

Today 08:18AM	Johnson & Johnson MedTech introduces electrosurgical generator (Medical Device Network)
08:03AM	New nipocalimab data and real-world research at AAN 2025 highlight positive Phase 3 results and commitment to people living with generalized myasthenia gravis (gMG) (PR Newswire)
06:20AM	Should First Trust Dow 30 Equal Weight ETF (EDOW) Be on Your Investing Radar? (Zacks)
Mar-25-25 01:11PM	Tevogen Bio Appoints David E. Banko as Global Head of Government Affairs and Patient Access, Advances Commercialization Plan (GlobeNewswire)
Mar-24-25 11:06PM	Wasatch Global Value Fund Q4 2024 Commentary (SeekingAlpha)
05:45PM	Loading…
05:45PM	Johnson & Johnson (JNJ) Stock Dips While Market Gains: Key Facts (Zacks)
03:00PM	ACIU Stock Crashes 18.3% in a Month: Buy, Sell or Hold? (Zacks)
01:56PM	Argenx: The Magic May Be Already Priced In (SeekingAlpha)
09:14AM	Is Johnson & Johnson (JNJ) The Best Healthcare Dividend Stock to Invest in? (InsiderMonkey)
08:39AM	Take the Zacks Approach to Beat the Markets: CMS Energy, Chevron, AutoZone in Focus (Zacks)
06:31AM	Here's How to Play JNJ Stock as it Announces $55B US Investment Plan (Zacks)
06:29AM	J&J to Invest $55B in United States to Boost Manufacturing, R&D (Zacks)
Mar-22-25 06:00PM	2 Dividend Picks Yielding Up To 5.67% For A Balanced Income & Growth Portfolio (SeekingAlpha)
03:06PM	Was Jim Cramer Right About Johnson & Johnson (JNJ)? (Insider Monkey)
01:50AM	The Davenport Insider Buying Fund Q4 2024 Commentary (SeekingAlpha)
02:41PM	Loading…
Mar-21-25 02:41PM	Johnson & Johnson is the latest pharma giant to court Trump with new investment plans (Quartz)
02:22PM	J&J boosts US operations with $55bn investment (Pharmaceutical Technology)
12:59PM	2025 Dividend Kings: Strong Run Continues (SeekingAlpha)
12:26PM	Pharma Stock Roundup: PFE's Final Haleon Stake Sale, AZN, SNY M&A Deals (Zacks)
11:31AM	The Art of Valuation: Discovering Johnson & Johnson's Intrinsic Value (GuruFocus.com)
11:05AM	J&J is latest company trying to get on Trump's good side with big U.S. investment (Investing.com)
10:09AM	Johnson & Johnson to Invest Over $55 Billion in U.S. in Next Four Years (The Wall Street Journal)
09:35AM	Stocks to Watch Friday: J&J, Nio, Micron, Carnival (The Wall Street Journal)
08:43AM	Investing in the U.S.: Tracking Corporate Spending Pledges Under Trump (The Wall Street Journal)
08:28AM	J&J's Tremfya Gets FDA Nod for 2nd IBD Condition Crohn's Disease (Zacks)
08:23AM	FDA Approves Johnson & Johnson's Tremfya For Crohn's Disease (Benzinga)
07:41AM	Johnson & Johnson plans $55 billion in US investments over the next four years (Associated Press Finance)
07:21AM	Merck Vs. Bristol-Myers Squibb: Which Pharma Stock Should You Buy (SeekingAlpha)
06:20AM	Is iShares Core High Dividend ETF (HDV) a Strong ETF Right Now? (Zacks)
06:07AM	J&J boosts investments in US to more than $55 billion amid looming tariff threats (Reuters)
06:00AM	Loading…
06:00AM	Johnson & Johnson Increases U.S. Investment to More than $55 Billion Over the Next Four Years (Business Wire)
05:20AM	FDA approves Johnson & Johnsons Tremfya to treat Crohns disease (Pharmaceutical Technology)
Mar-20-25 08:05PM	Historic Dividend Outperformance (SeekingAlpha)
06:12PM	U.S. FDA approves TREMFYA (guselkumab), the first and only IL-23 inhibitor offering both subcutaneous and intravenous induction options, for adult patients with moderately to severely active Crohn's disease (PR Newswire)
01:43PM	BofA picks 36 stocks to help weather market downturns (SeekingAlpha)
11:20AM	Defensive Stocks For Unpredictable Trump Policy (SeekingAlpha)
09:40AM	My Dividend Stock Portfolio: New February Dividend Record - 100 Holdings With 11 Buys (SeekingAlpha)
08:45AM	Pfizer Sells Remaining 7.3% Stake in Haleon for Around 3.3B (Zacks)
08:00AM	RYBREVANT (amivantamab-vmjw) plus LAZCLUZE (lazertinib) significantly outperforms standard of care in first-line EGFR-mutated lung cancer with compelling new data at ELCC 2025 (PR Newswire)
06:20AM	Should You Invest in the VanEck Pharmaceutical ETF (PPH)? (Zacks)
04:45AM	Honeywell Isn't Going to Let a Little Breakup Ruin Its Growth Plans (Motley Fool)
Mar-19-25 10:59AM	JNJ's Nipocalimab Gets FDA's Fast Track Tag for Sjogren's Disease (Zacks)
05:00AM	The Zacks Analyst Blog Highlights Visa, Johnson & Johnson, Thermo Fisher and AMREP (Zacks)
Mar-18-25 08:03AM	Nipocalimab, the first and only investigational treatment to be granted U.S. FDA Breakthrough Therapy designation for the treatment of adults with moderate-to-severe Sjögren's disease, has now received Fast Track designation (PR Newswire)
04:34AM	Got $300? Buy These 3 Top Dividend Stocks and Never Look Back. (Motley Fool)
Mar-17-25 07:26PM	Jim Cramer Says Johnson & Johnson (JNJ) Stock Could Fall to $160 Level (Insider Monkey)
05:45PM	Johnson & Johnson (JNJ) Rises But Trails Market: What Investors Should Know (Zacks)
08:45AM	Resilient Investing: 3 Stocks Built to Weather Market Volatility (MarketBeat)
04:41AM	The S&P 500 Is in Correction Territory: 4 Surefire Stocks to Buy Right Now (Motley Fool)
Mar-14-25 11:45AM	Johnson & Johnson (JNJ) Could Be a Great Choice (Zacks)
10:26AM	Hostage to Legal Decisions Heres Why Jim Cramer Gave Up on Johnson & Johnson (JNJ) (Insider Monkey)
05:30AM	Big Pharma Walked Away From Mental Health. Why Some Are Coming Back. (The Wall Street Journal)
05:01AM	Q4 Earnings Recap: Supernus Pharmaceuticals (NASDAQ:SUPN) Tops Branded Pharmaceuticals Stocks (StockStory)
Mar-13-25 08:19PM	Johnson & Johnson (JNJ): Breakout or Breakdown? Jim Cramer Says JNJ Must Fall for Market to Bottom (Insider Monkey)
06:16AM	FDA grants 510(k) clearance for J&J MedTechs Monarch Quest (Medical Device Network)
06:00AM	J&Js Monarch robot wins FDA nod for AI software update (MedTech Dive)
Mar-12-25 02:26PM	Why Johnson & Johnson (JNJ) is the Best Pharma Stock to Buy According to Hedge Funds (Insider Monkey)
09:47AM	Johnson & Johnson (JNJ): Among Dobermans of the Dow to Buy (Insider Monkey)
09:00AM	Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know (Zacks)
08:15AM	A new obesity biotech launches; Gilead plans to quickly advance once-yearly PrEP for HIV (BioPharma Dive)
Mar-11-25 12:07PM	Is Johnson & Johnson (JNJ) the Best Low Risk Stock to Buy In 2025? (Insider Monkey)
11:21AM	Cramer's Mad Dash: Johnson & Johnson (CNBC TV)
10:20AM	Genmab says J&J not exercising option on HexaBody-CD38 (TipRanks)
09:29AM	Protagonist Therapeutics Soars as Icotrokinra Drives Breakthrough Success (GuruFocus.com)
08:37AM	J&J and Protagonists icotrokinra scores in Phase IIb UC study (Clinical Trials Arena)
07:06AM	Genmab sinks as J&J opts not to develop Darzalex successor; stock upgraded (Investing.com)
Mar-10-25 04:30PM	Protagonist Therapeutics Unveils 'Paradigm-Shifting' Drug And Breaks Out (Investor's Business Daily)
03:30PM	How Exxon Mobil, Johnson & Johnson, And Cogent Communications Can Put Cash In Your Pocket (Benzinga)
03:14PM	Johnson & Johnson's Ulcerative Colitis Drug Hits Key Trial Goals, Stock Rises (GuruFocus.com)
08:30AM	Health Canada authorizes LAZCLUZE® (lazertinib) in combination with RYBREVANT® (amivantamab) as a first-line chemotherapy-free treatment for patients with EGFR-mutated advanced lung cancer (PR Newswire)
08:00AM	Icotrokinra meets primary endpoint of clinical response in ulcerative colitis study and shows potential to transform the treatment paradigm for patients (PR Newswire)
Mar-09-25 05:13PM	Is Johnson & Johnson (JNJ) the Best Performing Dividend Stock to Buy Now? (Insider Monkey)
Mar-08-25 11:21AM	CDC plans study into potential vaccines, autism connections, Reuters reports (TipRanks)
09:00AM	Icotrokinra results show potential to set a new standard of treatment in plaque psoriasis (PR Newswire)
Mar-07-25 12:26PM	J&J drops Phase III MDD programme due to lack of efficacy (Clinical Trials Arena)
12:13PM	Jim Cramer on Johnson & Johnson (JNJ): This Stock Has Been a Horse! (Insider Monkey)
09:03AM	Johnson & Johnson Stops Late-Stage Depression Study Over 'Insufficient Efficacy' (Benzinga)
07:08AM	J&J scraps depression testing for potential blockbuster drug (BioPharma Dive)
Mar-06-25 08:00PM	Finance Executives Seek Stability Amid Erratic Tariff Shifts (The Wall Street Journal)
12:33PM	Is Johnson & Johnson (JNJ) the Best Holding Company Stock to Buy Right Now? (Insider Monkey)
11:47AM	CFOs Give Leadership Advice for Tumultuous Times (WSJ)
04:06AM	2 Dow Stocks to Buy Hand Over Fist in March and 1 to Avoid (Motley Fool)
Mar-05-25 04:30PM	Johnson & Johnson to Host Investor Conference Call on First-Quarter Results (Business Wire)
03:39PM	Johnson & Johnson and 4 Other Biopharmaceutical Stocks That Might Be Ready to Break Out (Barrons.com)
02:36PM	Is Johnson & Johnson (JNJ) the Best Dividend Stock to Buy According to Billionaires? (Insider Monkey)
01:31PM	5 Big Biopharmaceutical Stocks That Are Finding Favor (Barrons.com)
09:45AM	What Trump's next batch of tariffs could mean for pharma industry (Yahoo Finance Video)
09:40AM	Why Johnson & Johnson (JNJ) is a Top Value Stock for the Long-Term (Zacks)
Mar-04-25 07:35PM	Johnson & Johnson (JNJ): Among Best Stocks To Invest In From Conservative Stock Portfolio (Insider Monkey)
05:26PM	Buy Johnson & Johnson (JNJ) Stock for Higher Highs? (Zacks)
04:15PM	Johnson & Johnson Announces Darren Snellgrove as Vice President, Investor Relations (Business Wire)
06:02AM	Unlocking Intrinsic Value: Analysis of Johnson & Johnson (GuruFocus.com)
04:06AM	Johnson & Johnson (JNJ): Among the Best S&P 500 Dividend Stocks to Buy Now (Insider Monkey)
Mar-03-25 05:45PM	Why the Market Dipped But Johnson & Johnson (JNJ) Gained Today (Zacks)
05:46AM	FDA recall notice details J&J pause of Varipulse (MedTech Dive)
Mar-02-25 07:38AM	3 Top High-Yield Dividend Stocks I Plan to Buy in March for More Passive Income (Motley Fool)
Mar-01-25 03:44PM	Johnson & Johnson (JNJ): Among the Best Psychedelic Stocks to Buy in 2025 (Insider Monkey)
05:51AM	3 Dividend Stocks That Are No-Brainer Buys Right Now (Motley Fool)
05:03AM	3 Top High-Yield Dividend Stocks I Just Bought in My Retirement Account (Motley Fool)
Feb-28-25 05:06AM	Wall Street's Greatest Dividend Stock Just Made History Again -- and 99.9% of Investors Have Never Heard of This Small-Cap Company (Motley Fool)

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Decker Robert J	VP Corporate Controller	Feb 25 '25	Option Exercise	101.87	6,999	712,988	28,000	Feb 26 06:42 PM
Decker Robert J	VP Corporate Controller	Feb 25 '25	Sale	165.88	6,999	1,160,994	21,001	Feb 26 06:42 PM
Decker Robert J	Officer	Feb 25 '25	Proposed Sale	165.88	6,999	1,161,010		Feb 25 03:05 PM
Schmid Timothy	EVP, WW Chair, MedTech	Feb 14 '25	Option Exercise	0.00	2,806	0	17,904	Feb 18 09:46 PM
Schmid Timothy	EVP, WW Chair, MedTech	Feb 15 '25	Option Exercise	0.00	1,029	0	15,501	Feb 18 09:33 PM
Schmid Timothy	EVP, WW Chair, MedTech	Feb 14 '25	Option Exercise	0.00	1,765	0	15,111	Feb 18 09:33 PM
Schmid Timothy	EVP, WW Chair, MedTech	Feb 13 '25	Option Exercise	0.00	499	0	13,539	Feb 18 09:33 PM
Schmid Timothy	EVP, WW Chair, MedTech	Feb 18 '25	Sale	156.15	403	62,928	15,098	Feb 18 09:33 PM
Wengel Kathryn E	EVP, Chief TO and Risk Officer	Feb 15 '25	Option Exercise	0.00	607	0	91,037	Feb 18 09:16 PM
Wengel Kathryn E	EVP, Chief TO and Risk Officer	Feb 14 '25	Option Exercise	0.00	7,367	0	96,674	Feb 18 09:16 PM
Wengel Kathryn E	EVP, Chief TO and Risk Officer	Feb 13 '25	Option Exercise	0.00	651	0	89,603	Feb 18 09:16 PM
Wolk Joseph J	Exec VP, CFO	Feb 15 '25	Option Exercise	0.00	1,971	0	6,113	Feb 18 09:13 PM
Wolk Joseph J	Exec VP, CFO	Feb 14 '25	Option Exercise	0.00	19,330	0	20,661	Feb 18 09:13 PM
Wolk Joseph J	Exec VP, CFO	Feb 13 '25	Option Exercise	0.00	1,779	0	1,779	Feb 18 09:13 PM
REED JOHN C	EVP, Innovative Medicine, R&D	Feb 15 '25	Option Exercise	0.00	1,350	0	15,927	Feb 18 09:11 PM
Taubert Jennifer L	EVP, WWC. Innovative Medicine	Feb 15 '25	Option Exercise	0.00	1,594	0	171,110	Feb 18 09:08 PM
Taubert Jennifer L	EVP, WWC. Innovative Medicine	Feb 14 '25	Option Exercise	0.00	19,518	0	185,924	Feb 18 09:08 PM
Taubert Jennifer L	EVP, WWC. Innovative Medicine	Feb 13 '25	Option Exercise	0.00	1,302	0	167,221	Feb 18 09:08 PM
Swanson James D.	EVP, CIO	Feb 15 '25	Option Exercise	0.00	492	0	16,762	Feb 18 09:06 PM
Swanson James D.	EVP, CIO	Feb 14 '25	Option Exercise	0.00	5,079	0	19,739	Feb 18 09:06 PM
Swanson James D.	EVP, CIO	Feb 13 '25	Option Exercise	0.00	447	0	15,019	Feb 18 09:06 PM
Mulholland Kristen	EVP, Chief HR Officer	Feb 15 '25	Option Exercise	0.00	419	0	13,095	Feb 18 09:05 PM
Mulholland Kristen	EVP, Chief HR Officer	Feb 14 '25	Option Exercise	0.00	2,608	0	14,576	Feb 18 09:05 PM
Mulholland Kristen	EVP, Chief HR Officer	Feb 13 '25	Option Exercise	0.00	411	0	12,100	Feb 18 09:05 PM
Forminard Elizabeth	Executive VP, General Counsel	Feb 15 '25	Option Exercise	0.00	961	0	10,321	Feb 18 09:03 PM
Forminard Elizabeth	Executive VP, General Counsel	Feb 14 '25	Option Exercise	0.00	2,203	0	11,366	Feb 18 09:03 PM
Forminard Elizabeth	Executive VP, General Counsel	Feb 13 '25	Option Exercise	0.00	651	0	8,991	Feb 18 09:03 PM
Duato Joaquin	CEO and Chairman of the Board	Feb 15 '25	Option Exercise	0.00	3,682	0	397,525	Feb 18 09:02 PM
Duato Joaquin	CEO and Chairman of the Board	Feb 14 '25	Option Exercise	0.00	24,335	0	415,205	Feb 18 09:02 PM
Duato Joaquin	CEO and Chairman of the Board	Feb 13 '25	Option Exercise	0.00	3,470	0	392,498	Feb 18 09:02 PM
Decker Robert J	VP Corporate Controller	Feb 15 '25	Option Exercise	0.00	339	0	20,116	Feb 18 09:01 PM
Decker Robert J	VP Corporate Controller	Feb 14 '25	Option Exercise	0.00	2,201	0	21,373	Feb 18 09:01 PM
Decker Robert J	VP Corporate Controller	Feb 13 '25	Option Exercise	0.00	312	0	19,285	Feb 18 09:01 PM
Broadhurst Vanessa	EVP, Global Corp Affairs	Feb 15 '25	Option Exercise	0.00	492	0	21,839	Feb 18 08:58 PM
Broadhurst Vanessa	EVP, Global Corp Affairs	Feb 14 '25	Option Exercise	0.00	4,740	0	24,591	Feb 18 08:58 PM
Broadhurst Vanessa	EVP, Global Corp Affairs	Feb 13 '25	Option Exercise	0.00	408	0	20,242	Feb 18 08:58 PM
Duato Joaquin	CEO and Chairman of the Board	Feb 07 '25	Option Exercise	100.06	126,369	12,644,482	489,671	Feb 11 07:43 PM
Wengel Kathryn E	EVP, Chief TO and Risk Officer	Feb 07 '25	Option Exercise	100.06	32,762	3,278,166	115,028	Feb 11 07:42 PM
Taubert Jennifer L	EVP, WWC. Innovative Medicine	Feb 07 '25	Option Exercise	100.06	58,504	5,853,910	213,355	Feb 11 07:41 PM
Wolk Joseph J	Exec VP, CFO	Feb 07 '25	Option Exercise	100.06	13,015	1,302,281	13,015	Feb 11 07:40 PM
Wolk Joseph J	Exec VP, CFO	Feb 07 '25	Sale	153.89	13,015	2,002,878	0	Feb 11 07:40 PM
Wolk Joseph J	Officer	Feb 07 '25	Proposed Sale	153.89	13,015	2,002,924		Feb 07 01:27 PM
WEINBERGER MARK A	Director	Dec 12 '24	Buy	147.22	1,000	147,220	1,000	Dec 12 05:27 PM
Hait William	Former Officer	Dec 04 '24	Proposed Sale	149.90	25,742	3,858,598		Dec 04 01:25 PM
Decker Robert J	VP Corporate Controller	Aug 30 '24	Option Exercise	100.06	5,635	563,838	24,608	Sep 03 04:48 PM
Decker Robert J	VP Corporate Controller	Aug 30 '24	Sale	165.06	5,635	930,113	18,973	Sep 03 04:48 PM
Decker Robert J	Officer	Aug 30 '24	Proposed Sale	165.06	5,635	930,113		Aug 30 03:51 PM
Broadhurst Vanessa	EVP, Global Corp Affairs	Jul 08 '24	Option Exercise	0.00	9,809	0	24,852	Jul 09 05:48 PM
REED JOHN C	EVP, Innovative Medicine, R&D	May 01 '24	Option Exercise	0.00	22,255	0	22,561	May 03 04:31 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

JNJ

Johnson & Johnson

Upgrade your FINVIZ experience